Needham & Company LLC Forecasts Strong Price Appreciation for Pacira BioSciences (NASDAQ:PCRX) Stock

Pacira BioSciences (NASDAQ:PCRX) had its price target increased by Needham & Company LLC from $22.00 to $30.00 in a research report released on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research analysts have also recently commented on PCRX. Royal Bank of Canada increased their price target on Pacira BioSciences from $15.00 to $16.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $39.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Barclays reduced their target price on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Finally, Jefferies Financial Group lifted their price target on Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $24.50.

Pacira BioSciences Stock Up 6.5 %

Shares of NASDAQ PCRX opened at $21.88 on Monday. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The stock’s fifty day moving average price is $18.52 and its two-hundred day moving average price is $17.52. Pacira BioSciences has a one year low of $11.16 and a one year high of $34.01.

Institutional Trading of Pacira BioSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pacer Advisors Inc. raised its holdings in shares of Pacira BioSciences by 129.4% in the third quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock valued at $74,681,000 after acquiring an additional 2,799,434 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Pacira BioSciences by 314.4% in the third quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock valued at $8,324,000 after buying an additional 419,656 shares in the last quarter. Doma Perpetual Capital Management LLC raised its position in shares of Pacira BioSciences by 71.8% during the 2nd quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock worth $28,632,000 after purchasing an additional 418,321 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Pacira BioSciences by 269.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock valued at $5,955,000 after acquiring an additional 288,662 shares in the last quarter. Finally, PDT Partners LLC purchased a new stake in shares of Pacira BioSciences during the 3rd quarter valued at approximately $3,469,000. 99.73% of the stock is owned by hedge funds and other institutional investors.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.